Balancing benefits and harms of treatments for acute bipolar depression

Journal of Affective Disorders

Volumn 169, Issue S1, 2014, Pages S24-S33

  Ketter, Terence A ^a   Miller, Shefali ^a,b   Dell'Osso, Bernardo ^a,c   Calabrese, Joseph R ^d   Frye, Mark A ^e   Citrome, Leslie ^f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antidepressants; Antipsychotics; Armodafinil; Bipolar depression; Bipolar disorder; Lamotrigine; Lurasidone; Mood stabilizers; Number needed to harm; Number needed to treat; Olanzapine plus fluoxetine; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ARMODAFINIL; CARBAMAZEPINE; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; LITHIUM; LURASIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG COMBINATION; FLUOXETINE; ISOINDOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ACUTE BIPOLAR DEPRESSION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; BODY WEIGHT DISORDER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NAUSEA; NUMBERS NEEDED TO HARM; NUMBERS NEEDED TO TREAT; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT RESPONSE; WEIGHT GAIN; ACUTE DISEASE; BIPOLAR DISORDER; DRUG COMBINATION; DRUG EFFECTS;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DRUG COMBINATIONS; FLUOXETINE; HUMANS; ISOINDOLES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TRIAZINES; WEIGHT GAIN;

EID: 84919668795     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/S0165-0327(14)70006-0     Document Type: Review

References (52)

1. Adler, C., Ketter, T., Frye, M.A., Yang, R., Bauer, M., 2014. Randomized, double-blind, placebo-controlled trial of adjunctive armodafinil (150 mg/day) in adults with bipolar I depression: Safety and primary efficacy findings. Presented at: 167th Annual Meeting of the American Psychiatric Association; May 3-7, 2014; New York, NY. Poster NR6-038.
2. L.L. Altshuler, M.J. Gitlin, J. Mintz, K.L. Leight, M.A. Frye Subsyndromal depression is associated with functional impairment in patients with bipolar disorder J. Clin. Psychiatry 63 9 2002 807 811
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fifth Edition 2013 American Psychiatric Association Arlington, VA
4. J.D. Amsterdam, J. Shults Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression - lack of manic induction J. Affect. Disord. 87 1 2005 121 130
5. R.J. Baldessarini, L. Leahy, S. Arcona, D. Gause, W. Zhang, J. Hennen Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders Psychiatr. Serv. 58 1 2007 85 91
6. JR Calabrese, MA Frye, R Yang, TA Ketter, Armodafinil Treatment Trial Study Network Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial J Clin Psychiatry 2014 published online ahead of print July 22, 2014.
7. J.R. Calabrese, R.F. Huffman, R.L. White, S. Edwards, T.R. Thompson, J.A. Ascher, E.T. Monaghan, R.A. Leadbetter Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials Bipolar Disord. 10 2 2008 323 333
8. J.R. Calabrese, P.E. Keck Jr., W. Macfadden, M. Minkwitz, T.A. Ketter, R.H. Weisler, A.J. Cutler, R. McCoy, E. Wilson, J. Mullen, the BOLDER Study Group A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression Am. J. Psychiatry 162 7 2005 1351 1360
9. J.R. Calabrese, J.R. Sullivan, C.L. Bowden, T. Suppes, J.F. Goldberg, G.S. Sachs, M.D. Shelton, F.K. Goodwin, M.A. Frye, V. Kusumakar Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management J. Clin. Psychiatry 63 11 2002 1012 1019
10. L. Citrome Can you interpret confidence intervals? It's not that difficult Curr. Psychiatr. 6 8 2009 77 82
11. L. Citrome Compelling or irrelevant? Using number needed to treat can help decide Acta Psychiatr. Scand. 117 6 2008 412 419
12. L. Citrome Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications Curr. Drug Saf. 4 3 2009 229 237
13. L. Citrome, T.A. Ketter, J. Cucchiaro, A. Loebel Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed J. Affect. Disord. 155 2014 20 27
14. J.B. Cohn, G. Collins, E. Ashbrook, J.F. Wernicke A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder Int. Clin. Psychopharmacol. 4 4 1989 313 322
15. Frye, M.A., Ketter, T.A., Bauer, M., Yang, R., Adler, C, 2014. Randomized, double-blind, placebo-controlled trial of adjunctive armodafinil (150 mg) in adults with bipolar I depression: safety and secondary efficacy findings. Presented at: 167th Annual Meeting of the American Psychiatric Association; May 3-7, 2014; New York, NY. Poster NR6-049.
16. M.A. Frye, T.A. Ketter, R. Yang Efficacy and safety of armodafinil as an adjunctive therapy for the treatment of a major depressive episode associated with bipolar I disorder Bipolar Disord. 15 s1 2013 126 127
17. J.R. Geddes, J.R. Calabrese, G.M. Goodwin Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Br. J. Psychiatry 194 1 2009 4 9
18. GlaxoSmithKline Lamictal® (lamotrigine) tablets [package insert] 2011 GlaxoSmithKline Research Triangle Park, NC
19. L.L. Judd, H.S. Akiskal, P.J. Schettler, W. Coryell, J. Endicott, J.D. Maser, D.A. Solomon, A.C. Leon, M.B. Keller A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder Arch. Gen. Psychiatry 60 3 2003 261 269
20. L.L. Judd, H.S. Akiskal, P.J. Schettler, J. Endicott, A.C. Leon, D.A. Solomon, W. Coryell, J.D. Maser, M.B. Keller Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study Arch. Gen. Psychiatry 62 12 2005 1322 1330
21. L.L. Judd, H.S. Akiskal, P.J. Schettler, J. Endicott, J. Maser, D.A. Solomon, A.C. Leon, J.A. Rice, M.B. Keller The long-term natural history of the weekly symptomatic status of bipolar I disorder Arch. Gen. Psychiatry 59 6 2002 530 537
22. T.A. Ketter, L. Citrome, P.W. Wang, J.L. Culver, S. Srivastava Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr. Scand. 123 3 2011 175 189
23. T.A. Ketter, P.W. Wang Overview of pharmacotherapy for bipolar disorders T.A. Ketter Handbook of Diagnosis and Treatment of Bipolar Disorders 1 ed. 2010 American Psychiatric Publishing, Inc. Arlington, VA 83 106
24. A. Laupacis, D.L. Sackett, R.S. Roberts An assessment of clinically useful measures of the consequences of treatment N. Engl. J. Med. 318 26 1988 1728 1733
25. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, J. Hsu, K. Sarma, G. Sachs Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2 2014 160 168
26. A. Loebel, J. Cucchiaro, R. Silva, H. Kroger, K. Sarma, J. Xu, J.R. Calabrese Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study Am. J. Psychiatry 171 2 2014 169 177
27. I. Lombardo, G. Sachs, S. Kolluri, C. Kremer, R. Yang Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J. Clin. Psychopharmacol. 32 4 2012 470 478
28. S.L. McElroy, R.H. Weisler, W. Chang, B. Olausson, B. Paulsson, M. Brecher, V. Agambaram, C. Merideth, A. Nordenhem, A.H. Young, EMBOLDEN II (Trial D1447C00134) Investigators A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J. Clin. Psychiatry 71 2 2010 163 174
29. K.R. Merikangas, H.S. Akiskal, J. Angst, P.E. Greenberg, R.M. Hirschfeld, M. Petukhova, R.C. Kessler Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 64 5 2007 543 552
30. C.J. Murray, A.D. Lopez Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study Lancet 349 9063 1997 1436 1442
31. C.B. Nemeroff, D.L. Evans, L. Gyulai, G.S. Sachs, C.L. Bowden, I.P. Gergel, R. Oakes, C.D. Pitts Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression Am. J. Psychiatry 158 6 2001 906 912
32. U. Osby, L. Brandt, N. Correia, A. Ekbom, P. Sparen Excess mortality in bipolar and unipolar disorder in Sweden Arch. Gen. Psychiatry 58 9 2001 844 850
33. M. Pompili, X. Gonda, G. Serafini, M. Innamorati, L. Sher, M. Amore, Z. Rihmer, P. Girardi Epidemiology of suicide in bipolar disorders: a systematic review of the literature Bipolar Disord. 15 5 2013 457 490
34. Z. Rihmer, K. Kiss Bipolar disorders and suicidal behaviour Bipolar Disord. 4 Suppl 1 2002 21 25
35. G.S. Sachs, K.S. Ice, P.B. Chappell, J.H. Schwartz, O. Gurtovaya, D.G. Vanderburg, B. Kasuba Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial J. Clin. Psychiatry 72 10 2011 1413 1422
36. G.S. Sachs, A.A. Nierenberg, J.R. Calabrese, L.B. Marangell, S.R. Wisniewski, L. Gyulai, E.S. Friedman, C.L. Bowden, M.D. Fossey, M.J. Ostacher, T.A. Ketter, J. Patel, P. Hauser, D. Rapport, J.M. Martinez, M.H. Allen, D.J. Miklowitz, M.W. Otto, E.B. Dennehy, M.E. Thase Effectiveness of adjunctive antidepressant treatment for bipolar depression N. Engl. J. Med. 356 17 2007 1711 1722
37. D.L. Sackett, S. Straus On some clinically useful measures of the accuracy of diagnostic tests ACP J. Club 129 2 1998 A17 A19
38. M. Sanford, G.M. Keating Quetiapine: a review of its use in the management of bipolar depression CNS Drugs 26 5 2012 435 460
39. H. Scherk, F.G. Pajonk, S. Leucht Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials Arch. Gen. Psychiatry 64 4 2007 442 455
40. R.C. Shelton, S.M. Stahl Risperidone and paroxetine given singly and in combination for bipolar depression J. Clin. Psychiatry 65 12 2004 1715 1719
41. M.M. Sidor, G.M. MacQueen Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis J. Clin. Psychiatry 72 2 2011 156 167
42. M.T. Silva, I.R. Zimmermann, T.F. Galvao, M.G. Pereira Olanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis J. Affect. Disord. 146 3 2013 310 318
43. L.A. Smith, V. Cornelius, A. Warnock, M.J. Tacchi, D. Taylor Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy Acta Psychiatr. Scand. 115 1 2007 12 20
44. A. Stang, C. Poole, R. Bender Common problems related to the use of number needed to treat J. Clin. Epidemiol. 63 8 2010 820 825
45. Teva Pharmaceutical Industries Ltd Teva reports top-line results from final phase III study of armodafinil (Nuvigil®) in patients with major depression associated with bipolar I disorder [press release]. August 30, 2013. Jerusalem, Israel, Teva Pharmaceutical Industries Ltd http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&id=1851019 Accessed October 17, 2014.
46. M.E. Thase, A. Jonas, A. Khan, C.L. Bowden, X. Wu, R.D. McQuade, W.H. Carson, R.N. Marcus, R. Owen Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies J. Clin. Psychopharmacol. 28 1 2008 13 20
47. M.E. Thase, W. Macfadden, R.H. Weisler, W. Chang, B. Paulsson, A. Khan, J.R. Calabrese, BOLDER II Study Group Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study) J. Clin. Psychopharmacol. 26 6 2006 600 609
48. M. Tohen, D.P. McDonnell, M. Case, S. Kanba, K. Ha, Y.R. Fang, H. Katagiri, J.C. Gomez Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression Br. J. Psychiatry 201 5 2012 376 382
49. M. Tohen, E. Vieta, J. Calabrese, T.A. Ketter, G. Sachs, C. Bowden, P.B. Mitchell, F. Centorrino, R. Risser, R.W. Baker, A.R. Evans, K. Beymer, S. Dubé, G.D. Tollefson, A. Breier Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression Arch. Gen. Psychiatry 60 11 2003 1079 1088
50. C.J. Truman, J.F. Goldberg, S.N. Ghaemi, C.F. Baldassano, S.R. Wisniewski, E.B. Dennehy, M.E. Thase, G.S. Sachs Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) J. Clin. Psychiatry 68 10 2007 1472 1479
51. H.M. Valtonen, K. Suominen, J. Haukka, O. Mantere, S. Leppamaki, P. Arvilommi, E.T. Isometsa Differences in incidence of suicide attempts during phases of bipolar I and II disorders Bipolar Disord. 10 5 2008 588 596
52. P.W. Wang, T.A. Ketter Management of acute major depressive episodes in bipolar disorders T.A. Ketter Handbook of Diagnosis and Treatment of Bipolar Disorder 2010 American Psychiatric Publishing Washington, DC 165 247